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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A162these channels was (51±16pS, n¼3). Following cytokine treatment, the
proportion of patches exhibiting chloride-like ion channel activity was
similar (4/9), however this included two conductance populations; one
similar to that seen under control conditions (87±19pS, n¼3), but also a
population of anion channels with signiﬁcantly greater unitary slope
conductances (214±39pS, p<0.05 n¼3).
Conclusions: In this simple model of inﬂammatory OA we have dis-
covered that an additional phenotype of ion channel becomes evident
following cytokine treatment, this is previously unreported at the single
channel level. The identity of these molecular markers is currently
unknown and future experiments will use a combination of physio-
logical, pharmacological andmolecular biological techniques to identify
putative changes in underlying anion channel gene expression.
Funding: The research leading to these results has receivedpartial funding
from the European Union Seventh Framework Programme (FP7/2007-
2013) under grant agreement number 305815 and the Royal Society.
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THE ROLE OF LIVER X RECEPTOR IN CHONDROCYTE
DIFFERENTIATION AND OSTEOARTHRITIS
M.-G. Sun, F. Beier. Univ. of Western Ontario, London, ON, Canada
Purpose: Activation of the Liver X Receptor (LXR) has recently been
identiﬁed as a potential therapeutic strategy for osteoarthritis (OA). In
particular, recent studies report that human OA articular cartilage
explants show decreased LXR expression, and LXRb-null mice display
OA-like symptoms. Additionally, LXR agonist administration to OA
articular cartilage explants suppresses proteoglycan degradation and
restores LXR-activated transcription. We investigate the effect of LXR
activation on chondrocyte differentiation to elucidate the molecular
mechanisms behind its protection against OA.
Methods: The speciﬁc LXR agonist, GW3965, was used to examine the
effect of LXR activation on chondrocyte differentiation. Tibia organ
cultures were used to examine the effect of LXR activation on bone
growth and growth plate morphology, followed by immunohis-
tochemical analysis. In ATDC5 and micromass cultures, chondrocyte
differentiation was examined through cellular staining and pro-
liferation assays. Various chondrogenic markers were analyzed through
qRT-PCR in micromass cultures. Affymetrix microarray analyses were
performed on primary mouse chondrocytes to examine differential
gene expression in response to GW3965 treatment.
Results: Chondrocyte hypertrophy was suppressed by GW3965 treat-
ment, as shown by decreased hypertrophic zone length in the tibia
growth plate, decreased alkaline phosphatase staining in ATDC5 and
micromass cultures, and down-regulation of Col10a1, Mmp13 and
Runx2 expression. Increased proliferation in treated ATDC5 cells, up-
regulation of Col2a1 expression in treated micromass cultures and
decreased p57 levels in treated growth plates suggest hypertrophy is
suppressed secondary to delayed cell cycle exit. Interestingly, LXR
activation decreased alcian blue staining in micromass cultures. Various
genes controlling lipid homeostasis, such as Abca1, Abcg1, and Srebf1
were signiﬁcantly up-regulated at least 1.5 fold in primary mouse
chondrocytes after GW3965 treatment in comparison to DMSO control.
Conclusions: Our ﬁndings demonstrate LXR activation in chondrocytes
suppresses chondrocyte hypertrophy in-vitro through cell-cycle exit
delay and retention of proliferation. Signiﬁcant up-regulation of lipid
homeostasis genes in response to GW3965 treatment suggests LXR
regulation of chondrogenic genes to be secondary to changes in lipid
metabolism. These studies on cartilage development provide insight
into how LXR activation prevents cartilage breakdown, further solid-
ifying its potential as a therapeutic target of OA.
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DISTINCT EXPRESSION OF SREBP-2 IN NORMAL AND
OSTEOARTHRITIC CHONDROCYTES
K. Tao, Sr. y,z, X. Tang y, B. Wang y, J.R. Li y, L. Jiang y, H.J. Lin y. y Peking
Univ. People's Hosp., Beijing, China; z Peking Univ. Hlth.Sci. Ctr., Beijing,
China
Purpose: Recent reports have elucidated that osteoarthritis (OA) is a
metabolic disease with the epigenetic and proteomic analysis studies for
various lipid metabolism-related genes and proteins comparing osteo-
arthritic cartilage with normal. Sterol regulatory element-binding protein
2 (SREBP2) is a ubiquitously expressed transcription factor that controlscholesterol homeostasis by stimulating transcription of sterol-regulated
genes, such as 3-hydroxy-3-methyl glutaryl CoA reductase (HMGCR) [1].
Apart from regulating cholesterol homeostasis, several studies have pro-
vided evidence that SREBP2 and its various single nucleotide poly-
morphisms (SNPs) also play an central role in the pathogenesis of
osteoarthritis, however, the association of SREBP2 with articular chon-
drocytes arthritogenic effects of IL-1beta (IL-1b) has been poorly under-
stood [2, 3]. In this study, we investigated the association between SREBP2
expression and IL-1b-induced articular chondrocytes arthritogenic effects.
Methods: Human cartilage were obtained from total knee arthroplasty
for osteoarthritis or total hip arthroplasty for fracture of neck of femur
(normal control group). Meanwhile, the normal and osteoarthritic carti-
lage isolated from of C57BL/6 mice and surgically induced osteoarthritis
models. Then, immunohistochemistry staining and quantitative real-
time polymerase chain reaction (qRT-PCR) were performed to detect the
expression of SREBP2,HMGCR, SOX9, type II collagen and typeX collagen.
Moreover, we treated normal chondrocytes with different concentration
of IL-1b, and examined the expression of the above genes.
Results:We found that the expression of SREBP-2, HMGCR, SOX9, type
II collagen and type X collagen in OA patients and normal controls were
signiﬁcantly different, and similar results obtained in the two C57BL/6
mice groups. After induced by IL-1b, normal chondrocytes turned
hypertrophy-like chondrocytes, and notably, the expression of SREBP-2,
type X collagen and HMGCR were upregulated, and SOX9 and type II
collagen were suppressed in vitro.
Conclusions: These data suggest that SREBP-2 has a distinct expression
in normal and osteoarthritic chondrocytes. Proinﬂammatory cytokine
IL-1b may inﬂuence the hypertrophy and function of chondrocyte in
part through SREBP-2.
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MITOCHONDRIA: A NEW CHONDROITIN SULPHATE THERAPEUTIC
TARGET FOR OSTEOARTHRITIS
V. Calamia, Sr. y, M. Lopez-Armada, Sr. y, E. Montell, Sr. z, J. Verges, Sr. z,
C. Ruiz-Romero, Sr. y, F.J. Blanco, Sr. y. yUniv.e da Coru~na, A Coru~na,
Spain; z Pre-Clinical R&D Area, Bioiberica, Barcelona, Spain
Purpose: In a recent proteomic study, we have demonstrated that
mitochondrial dysregulation occurs in cartilage cells during osteo-
arthritis (OA). These ﬁndings suggest that mitochondriarepresent an
attractive target for anti-OA pharmacotherapy. In this study we have
investigated the mitochondrial activity of OA human articular chon-
drocytes treated with chondroitinsulphate (CS).
Methods: Chondrocytes were released by enzymatic digestion from OA
human cartilages (n¼8). The study was approved by the local ethic com-
mittee (Galician). Once reached 80% conﬂuence, cellswere treatedwith CS
(Bioiberica, Spain) inpresence or absenceof different stimuli (IL1b5ng/ml,
TNFa 10 ng/ml and LPS 100mg/ml). Cells were analyzed by ﬂow cytometry
tomeasure themitochondrialmembrane potential (Djm)using the probe
JC-1 (10 mg/ml) and to evaluate the intracellular production of ROS using
the dye DCFH-DA (10 mM). ATP Bioluminiscence Assay Kit (PerkinElmer)
was utilized to measure the production of intracellular ATP. A commercial
colorimetric assay kit (Sigma) was used to speciﬁcally quantify mito-
chondrial superoxide dismutase activity (SOD2).NOreleasewasmeasured
as nitrite concentration in 48 h culture supernatants by using the Griess
assay. SPSS statistical software was used to determine statistical sig-
niﬁcance by using U-Mann Whitney test (p  0.05).
Results: At basal condition, a 64% increase in chondrocytes Djm was
observed after 48 hours treatment with CS 200 mg/mL. When chon-
drocytes were stimulated with TNFa, a signiﬁcant depolarization was
induced (Djm decreased up to 41% and 39% respectively). Interestingly,
also in this case, CS was able to increase chondrocytes Djm up to 66%,
partially counteracting the effect of TNFa. To determine mitochondrial
function, we also assessed ATP production. Chondrocytes treatment with
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A163CS 200 mg/mL at 24 hours signiﬁcantly increased ATP production com-
pared to basal condition (0,55 mM vs 0,65 mM). After TNFa stimulation,
ATP production fell to 0,40 mM; but also in this case, CSwas able to inhibit
TNFa effect increasing the ATP synthesis up to 0,62 mM. Furthermore, we
have evaluated the effect ofCS on NO and ROS production. CS was able to
reduce NO synthesis induced by IL1b, TNFa or LPS. The NO levels were
reduced after cytokine stimulation up to 21%, 32% and 31% respectively.
On the other hand, in presence of IL1b, ROS production and SOD2 activity
were increased. In this case, intracellular ROS production as well as SOD
activity decreased in CS treated chondrocytes at an average of 80%. The
decreasewasmoremarked (up to 62%)whenwe speciﬁcally analysed the
mitochondrial isoform of this important antioxidant enzyme (SOD2).
Conclusions: In summary, CS improves mitochondrial activity in
human OA chondrocytes by affecting several mitochondrial processes.
The mitochondrial membrane hyperpolarization and the increased ATP
production could correlate with a greater resistance of CS treated
chondrocytes to apoptosis.Moreover, the reduction of NO and ROS
levels, as well as the reduction in SOD2 activity, provide evidence of the
effect of CS on oxidative stress regulation.
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EFFECT ON THE CHONDROCYTE PHENOTYPE BY SPECIFICALLY
INHIBITING THE b-CATENIN DEPENDENT WNT SIGNALING USING
SMALL PEPTIDES
A. Held y, A. Glas z, T. Grossmann z, T. Pap y, J. Bertrand y. y Inst. of
Experimental Musculoskeletal Med., Munster, Germany; zChemical
Genomics Ctr. (CGC) of the Max Planck Society, Dortmund, Germany
Purpose: In osteoarthritis (OA), chondrocytes undergo hypertrophic
differentiation. In course of phenotypic change of chondrocytes, the
matrix is remodeled, including down-regulation of genes such as ACAN,
COL2A1 and MMP13. One of the signaling pathways involved in this
chondrocyte differentiation is the canonical b-catenin dependent WNT
signaling pathway. SAH-BCL9 (stabilized alpha-helix of Bcl9) and StAx-
35R (stapled axin b-catenin binding domains), two small peptides have
been developed to inhibit the oncogenic canonical- WNT signaling by
directly targeting b-catenin. We hypothesized that SAH-BCL9 and StAx-
35R may inhibit the dedifferentiation of chondrocytes towards hyper-
trophy and may reduce OA-like changes in the cartilage.
Methods: In vitro analyses were performed using primary chondrocytes
isolated from neonatal mice. The peptides SAH-BCL9 and StAx-35R were
synthesized and provided by the Grossmann Lab at the Chemical
Genomics Centre (CGC) of theMax Planck Society in Dortmund, Germany.
Micromass cultures were stained with alcian blue to examine the pro-
teoglycanproduction. Expressionofmarkergenes (ACAN,COL2A1,MMP13
and AXIN2)wasmeasured by quantitative RT-PCR. Effects of the inhibitors
on the phosphorylation of LRP6 and on total b-catenin were analyzed
using Western Blot. With dual luciferase assays the efﬁcacy of the inhib-
itors on the TCF/LEF blockade was tested. Intracellular localization of the
inhibitors was investigated by using confocal laser microscopy.
Results: Based on ﬁrst results, confocal laser microscopy demonstrated
intracellular but not intranuclear localization of FITC-labeled SAH-BCL9
and StAx-35R peptides in primary chondrocytes and C28 cells, chon-
drocyte-like immortalized cells. Treatment of hip caps with inhibitors
showed better penetration into cartilage for SAH-BCL9, but not for StAx-
35R, independent of previous IL-1 treatment. TCF/LEF promotor activity
was reduced by application of increasing concentrations of SAH-BCL9,
but not with StAx-35R, upon simultaneous induction of the canonical
WNT signaling with WNT3A. Western blot analysis revealed that StAx-
35R did not affect pLRP6 and b-catenin. However ﬁrst results indicated
less phosphorylation of LRP6 and less stabilization of b-catenin when
cells were treated with SAH-BCL9 and WNT3A compared to cells which
were only treated with WNT3A alone. Quantitative RT-PCR showed
decreased expression of aggrecan, collagen type II and MMP13 upon
stimulation with WNT3A, which was not rescued to baseline by treat-
ment withWNT3A and either one of the inhibitors. Expression of Axin2,
a target gene of the canonical WNT signaling pathway, was increased by
WNT3A and still enhanced when cells were treated simultaneously
withWNT3A and SAH-BCL9 or StAx-35R.With regard to the phenotypic
stability of chondrocytes, alcian blue staining of micromass cultures
showed that WNT3A treatment led to proteoglycan loss, which could
not be reduced by using the small peptides.
Conclusions: Our data indicate that SAH-BCL9 inhibits the b-catenin
dependent WNT signaling pathway on protein level and functionally
with regard to the TCF/LEF reporter activity at high concentrations.Despite both - SAH-BCL9 and StAx-35R - appear to be not able to reverse
WNT3A induced changes on the chondrocyte phenotype.
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EFFECT OF GROWTH HORMONE AND HYALURONAN AMIDE
DERIVATIVE ON HUMAN OSTEOARTHRITIC CHONDROCYTES
F. Paolella y, E. Gabusi y, C. Manferdini y, L. Gambari y, A. Schiavinato z,
B. Grigolo y, G. Lisignoli y. y Istituto Ortopedico Rizzoli, Bologna, Italy;
z Fidia Farmaceutici s.p.a., Abano Terme, Padova, Italy
Purpose: Knee osteoarthritis (OA) is one of the main causes of pain and
disability and signiﬁcantly affects the patients’ quality of life. The
homeostasis of articular cartilage is mediated by a complex network of
interactions mainly due to locally produced growth factors, ECM com-
ponents and circulating hormones. The development of pharmaco-
logical treatments with the potential for structure-modifying activity in
OA joint treatment has become a major focus in the ﬁeld of OA research.
Aim of this study was to evaluate the effects of hyaluronan amide
derivative (HYADD®4-G, HAD) alone or in combination with human
growth hormone (hGH) on OA chondrocytes.
Methods: Chondrocytes were isolated from cartilage of OA patients
undergoing knee arthroplasty. Chondrocytes were treated with differ-
ent concentrations of hGH (from 0.01mg/ml to10mg/ml) with or without
HAD (1mg/ml) and analyzed at different time points (24, 48, 72 hours
and after 7 days). They were analyzed for: 1.the presence of GHR and
CD44 by immunocytochemistry, 2. cell viability by vital dye, 3. meta-
bolic activity by alamar blue assay, 4. the release of IGF-1, FGF2 and IL6
by immunoassay tests, 5. gene expression of collagen type 1, collagen
type 2, collagen type 10 and SOCS2 by qRT-PCR.
Results: OA chondrocytes express GH receptor and all doses of hGH
tested not affected cell viability and metabolic activity, as well as, the
expression of collagen type 2, 1, or 10 and the release of insulin like
growth factor-1 (IGF-1) or ﬁbroblast growth factor-2 (FGF-2) or IL6. hGH
treatment increased the expression of hyaluronan receptor CD44. HAD
alone or combined with hGH reduced metabolic activity, the release of
IL6 and the gene expression of collagen type 1, 2 and 10 , except SOCS2,
that was increased. Interestingly, all the parameters analyzed propor-
tionally decreased with increasing age of the patients.
Conclusions: hGH did not induce human chondrocyte metabolic
activity and did not affect typical chondrocytic (collagen type 2) or
ﬁbrotic or hypertrophic (collagen type 1 and 10) marker expression or
IGF1 or FGF2 or IL6 release but induced CD44 receptor. HAD reduced all
the effects induced by hGH on human OA chondrocytes partially
through a signiﬁcant induction of SOCS2 expression. It has been dem-
onstrated that SOCS2 is signiﬁcantly reduced in OA chondrocytes and
our preliminary results demonstrate an unknown interplays between
hGH and hyaluronic acid probably due to SOCS2.
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SANGUIS DRACONIS RESIN STIMULATES THE OSTEOGENESIS IN
OSTEOBLASTIC MC3T3-E1 CELLS IN VITRO
W. Wang y, P. Yuan z, X. Guo x. y The Second Afﬁliated Hosp., Xian Jiaotong
Uinversity, Xian, China; z Shaanxi Traditional Chinese Med. Coll., Xianyang,
China; xDept. of Publ. Hlth., Med. Coll., Key Lab. of Environment and Genes
Related to Diseases, Xian Jiaotong Uinversity, Xian, China
Purpose: Sanguis Draconis (SD)is a resin that is obtained from Dae-
monorops draco (Palmae). Used in traditional medicine, it has shown
activity in the prevention of osteoporosis as well as promoting the
healing of bone fractures.The purpose of this study was to investigate
the effect of SD on the MC3T3-E1 cells in vitro.
Methods: In this study, the effects of Sanguis Dranonis ethanol extract
on b-glycerolphosphate and ascorbic acid induced differentiation using
mouse calvaria origin MC3T3-E1 osteoblastic cells was examined. We
looked at osteoblast differentiation, proliferation, andmineralization by
measuring alkaline phosphatase (ALP) and speciﬁc bone marker activ-
ities. Osteoblast-like MC3T3-E1 cells were cultured in various concen-
trations of SD ethanol extract (0.005-1 mg/mL) during the osteoblast
differentiation period (1, 5, 15, and 25 days).
Results: As measured by 3-[4,5-dimethylthiazol-2-y]-2,5-diphenylte-
trazolium bromide assay, SD extracts increased cell proliferation as
compared to control. The most pronounced effect was observed at the
concentration range between 0.01 and 0.1 mg/mL (P<0.01). This SD
stimulatory effect for cell proliferation was observed during the whole
